Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
MMW - Fortschritte der Medizin
Erschienen in: MMW - Fortschritte der Medizin 8/2017

02.05.2017 | Aktinische Keratose | FORTBILDUNG . ÜBERSICHT

Haut retten, Karzinome verhindern

Die Prävention und Therapie Aktinischer Keratosen

verfasst von: Prof. Dr. med. Harald P. M. Gollnick (em)

Erschienen in: MMW - Fortschritte der Medizin | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

In einem früheren CME-Kurs der MMW (MMW. 2017;159(Sonderheft 1):57-62) konnten Sie lernen, wie Sie Aktinische Keratosen erkennen können. Was Sie Ihren Patienten bezüglich der primären bzw. sekundären Prävention raten können und welche Behandlungsmöglichkeiten es gibt, erfahren Sie in diesem Beitrag.
Literatur
1.
Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, Eberle J, Terhorst D, Sterry W, Stockfleth E. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol. 2009;161:78–84CrossRefPubMed
2.
Grundmann J, Gollnick H. Präventivmaßnahmen gegen UV-Lichtschäden: äußerer und innerer Lichtschutz. Therapeutische Umschau.1999;56:225–32CrossRefPubMed
3.
Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329:1147–51CrossRefPubMed
4.
Green A, Williams G, Neale R et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: a randomised controlled trial. Lancet. 1999;354:723–9CrossRefPubMed
5.
Greul AK, Grundmann JU, Heinrich F, Pfitzner I, Bernhardt J, Ambach A Biesalski HK, Gollnick H. Photoprotection of UV-Irradiated Human Skin: An Antioxidative Combination of Vitamins E and C, Carotenoids, Selenium and Proanthocyanidins. Skin Pharmacol Appl Skin Physiol. 2002;15:307–15CrossRefPubMed
6.
Darlington S, Williams G, Neale R et al. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol. 2003;139:451–5CrossRefPubMed
7.
Biesalski H, Hemmes Ch, Hopfenmüller W, Schmid Ch, Gollnick H. Effects of controlled exposure of sunlight on plasma and skin levels of ß-carotene. Free Rad Res. 1996;24:215–24CrossRef
8.
Gollnick H, Hopfenmüller W, Hemmes Ch, Chun S, Schmid Ch, Sundermeier K, Biesalski H. Systemic beta carotene plus topical UV-sunscreen are an optimal protection against harmful effects of natural UV-sunlight: results of the Berlin-Eilath study. Eur J Dermatol. 1996;6:200–5
9.
Nichols B, Amber HA, Shareef Sh, Badiavas DV, Kirsner RS, Ioannidis T. Association of HPV vaccine with development of keratinocyte carcinomas. JAMA Dermatol. 2017; doi: 10.1001/jamadermatol.2016.5703. [Epub ahead of print]
10.
Hughes MC, van der Pols JC, Marks GC, Green AC. Food intake and risk of squamous cell carcinoma of the skin in a community: The Nambour skin cancer cohort study. IJC. 2006;119:1953–60
11.
Werner RN, Sammain A, Erdmann R et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169:502–18CrossRefPubMed
12.
Dirschka T, Pellacani G. Micali G, Malvehy J, Stratigos AJ, Casari A, Schmitz L, Gupta G. Athens AK Study Group. A Proposed Scoring System for Assessing the Severity of Actinic Keratosis on the Head: Actinic Keratosis Area and Severity Index (AKASI). J Eur Acad Dermatol Venereol. 2017; doi: 10.1111/jdv.14267. [Epub ahead of print]
13.
Stockfleth E et al. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Eur J Dermatol. 2014;24:23–7PubMed
14.
Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. Plast Reconstr Surg. 1987;80:47–54CrossRefPubMed
15.
Winton GB, Salasche SJ. Dermabrasion of the scalp as a treatment for actinic damage. J Am Acad Dermatol. 1986;14:661–8CrossRefPubMed
16.
Coleman WP 3rd, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg. 1996;22:17–21PubMed
17.
Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2006;142:976–82PubMed
18.
Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C, Sidoroff A, Hempel M, Ulrich J, Proebstle T, Meffert H, Mulder M, Salomon D, Dittmar HC, Bauer JW, Kernland K, Braathen L. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:258–262CrossRefPubMed
19.
Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol. 2008 Jul;7:669–73PubMed
20.
Lubritz RR, Smolewski SA. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol. 1982;7:631–2CrossRefPubMed
21.
Kalivas J. Cryosurgery of actinic keratoses: the patient’s perspective. Dermatol Surg. 1996;22:486CrossRefPubMed
22.
Thai KE, Fer gin P, Freeman M et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004;43:687–92CrossRefPubMed
23.
Zouboulis CC, Röhrs H. Cryosurgical treatment of actinic keratoses and evidence-based review. Hautarzt. 2005;56:353–8CrossRefPubMed
24.
Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratoses: an update and comparison. Dermatol Surg. 2000;26:728–32CrossRefPubMed
25.
Iyer S, Friedli A, Bowes L, Kricorian G, Fitzpatrick RE. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med. 2004;34:114–9CrossRefPubMed
26.
Wollina U, Konrad H, Karamfilov T. Treatment of common warts and actinic keratoses by Er:YAG laser. J Cutan Laser Ther. 2001;3:63–6CrossRefPubMed
27.
Sherry SD, Miles BA, Finn RA. Long-term efficacy of carbon dioxide laser resurfacing for facial actinic keratosis. J Oral Maxillofac Surg. 2007;65:1135–9CrossRefPubMed
28.
Fulton JE, Rahimi AD, Helton P, Dahlberg K, Kelly AG. Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg. 1999;25:729–32CrossRefPubMed
29.
Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, Thai KE, Murrell D, Weightman W, Anderson C, Reid C, Watson A, Foley P. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treatm. 2003;14:99–106CrossRef
30.
Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol. 2006;86:25–8PubMed
31.
Perrett CM, McGregor JM, Warwick J et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. 2007;156:320–8CrossRefPubMedPubMedCentral
32.
Hohwy T, Andersen KE, Sølvsten H, Sommerlund M. Allergic contact dermatitis to methyl aminolevulinate after photodynamic therapy in 9 patients. Contact Dermatitis. 2007;57:321–3CrossRefPubMed
33.
Kerrouche N, Szeimies R-M. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. JEADV. 2015;29:2342–8PubMed
34.
Wiegell SR, Wulf HC, Szeimies RM, Basset-Seguin N et al. Daylight photodynamic therapy for actinic keratosis: an international consensus. JEADV. 2011:26:673–79PubMed
35.
Wiegell SR, Fabricius S, Heydenreich J, Enk CD, Rosso S, Bäumler W, Baldursson BT, Wulf HC. Weather conditions and daylight-mediated photodynamic therapy: protoporphyrin IX-weighted daylight doses measured in six geographical locations. Br J Dermatol. 2013;168:186–91CrossRefPubMed
36.
Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002;302:18–25CrossRefPubMed
37.
Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). Br J Dermatol. 2007;156(Suppl. 3):25–33CrossRefPubMed
38.
Quist S, Wiswedel I, Quist J, Gollnick H. Kinetic profile of inflammation markers in human skin in vivo following UV exposure to UVB indicates synchronic release of cytokines and prostanoids. ActaDermVenereol. 2016;96:910–6
39.
Wiswedel I, Keilhoff G, Dörner L, Navarro A, Böckelmann R, Bonnekoh B, Gardemann A, Gollnikc H. UVB irradiation-induced impairment of keratinocytes and adaptive responses to oxidative stress. Free Radical Res. 2007;41:1017–27CrossRef
40.
Wolf JR, Taylor JR, Tschen E. Topical 3% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol, 2001;40:709–13CrossRefPubMed
41.
Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol. 2003;44:40–3CrossRefPubMed
42.
Smith S, Piacquadio D, Morhenn V, Atkin D, Fitzpatrick R. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol.2003;2:629–35PubMed
43.
Pirard, D, Vereecken, P, Mélot, C, Heenen, M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res. 2005;297:185CrossRefPubMed
44.
Rivers JK, Arlette J, Shear N et al. Topical treatment of actinic keratoses with 3,0% diclofenac in 2,5% hyaluronan gel. Br J Dermatol. 2002;146:94–100CrossRefPubMed
45.
Dirschka T, Bierhoff E, Pflugfelder A, Garbe C. Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses. J Eur Acad Dermatol Venereol. 2010;24:258–63CrossRefPubMed
46.
Stockfleth E, Terhorst D, Hauschild A, Zouboulis CC, Schlaeger M, Oster-Schmidt C, Diepgen TL, Garbe C, Gollnick H, Korting HC, Merk H, Sterry W, Kerl H, Berking C. Aktinische Keratosen. JDDG. 2012;10(Suppl 7):S1–S23CrossRef
47.
Smith, SR, Morhenn, VB, Piacquadio, DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5:156PubMed
48.
Kowalzick L, Ziegler H. Photoallergic contact dermatitis from topical diclofenac in Solaraze gel. Contact Dermatitis. 2006;54:348–9CrossRefPubMed
49.
Micali G, Lacarrubba F, Nasca MR, Ferraro S, Schwartz RA.Topical pharmacotherapy for skin cancer: part II. Clinical applications. JAmAcadDermatol. 2014;70:979.e1–e12
50.
Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9:209–14CrossRefPubMed
51.
Epstein, E. Twice daily vs. four times daily 5-fluorouracil therapy for actinic keratoses: a split face study. Br J Dermatol. 2006;154:794–5CrossRefPubMed
52.
Jury CS, Ramraka-Jones VS, Gudi V, Herd RM. A randomized trial of topical 5% 5-fluorouracil in the treatment of actinic keratoses comparing daily with weekly treatment. Br J Dermatol. 2005;153:808–10CrossRefPubMed
53.
Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, Hahn S, Lau K, Jäger A, Schmitz B, Lübbert H, Szeimies RM. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED(®) lamp. Br J Dermatol. 2016;175:696–705CrossRefPubMed
54.
Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB: Life threatening toxicity in a dihydropyrimidin-dehydrogenase-deficiency patient after treatment with topical 5-fluorouracil. Clin Cancer Res. 1999;5:2006–11PubMed
55.
Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dos 5 fluorouracil in combination with salicylic acid as a new lesion directed option to treat topically actinic keratosis histological and clinical results. Br J Dermatol. 2011;165:1101–8CrossRefPubMed
56.
Meijer BU, de Waard-van der Spek FB. Allergic contact dermatitis because of topical use of 5-fluorouracil (Efudix cream). Contact Dermatitis. 2007;57:58–60CrossRefPubMed
57.
Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196–200CrossRefPubMed
58.
Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1–14CrossRefPubMed
59.
Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schön MP (2003) Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 95:1138–49CrossRefPubMed
60.
Brown VL, Atkins CL, Ghali L, Cerio R, Harwood CA, Proby CM. Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. Arch Dermatol. 2005;141:985–93PubMed
61.
Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of Imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol. 2007;157:133–41CrossRefPubMed
62.
Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2006;55:537–8CrossRefPubMed
63.
Quist SR, Gollnick HP. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratosis. Expert Opinion on Pharmacotherapy. 2011;12:451–61CrossRefPubMed
64.
Stockfleth E et al. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%. Eur J Dermatol. 2014;24:23–7PubMed
65.
Samorano LP et al. Evaluation of the tolerability and safety of a 0.015% ingenolmebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial keratosis: a prospective randomized trial. J Eur Acad Dermatol Venereol. 2015;29:1822–7CrossRefPubMed
66.
Garbe C, Basset-Seguin N, Poulin Y,Larsson T, Østerdal ML, Venkata R, Lear JT. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0,015% gel: a randomized, controlled 12-month study. Br J Derm. 2016;174:505–13CrossRef
67.
68.
Stüttgen, G. Zur Lokalbehandlung von Keratosen mit Vitamin-A-Säure. Dermatologica 1962;124:65CrossRef
69.
Kligman AL, Thorne EG. Topical therapy of actinic keratoses with tretinoin. In: Retinoids in Cutaneous Malignancy (Marks R, ed.), Oxford: Blackwell Scientific Publications, 1991; S.66–73
70.
Gollnick H, Göppner A. Retinoide. — In: Tumoren der Haut / hrsg. von R.-M. Szeimies Stuttgart [u.a.]: Thieme 2010, S. 185–93
71.
Göppner A, Gollnick H. Skin Cancer: Antioxidants and Diet. In: Jemec, Gregor (Eds.). — Non-surgical treatment of keratinocyte skin cancer. —Springer Heidelberg, Berlin, New York. 2010, S.177–185CrossRef
72.
Yiasemides E, Sivapirabu G, Halliday GM, Park J, Damian DL. Oral nicotinamide protects against ultraviolet radiation induced immunosuppression in humans. Carcinogenesis. 2009;30:101–5CrossRefPubMed
73.
Surjana D, Halliday GM, Martin AJ, Moloney FJ, Damian DL. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol. 2012;132:1497–500.CrossRefPubMed
74.
Chen A, Chen C, Martin AJ, Choy B, Fernandez-Penas P, Dalziell RA, McKenzie CA, Richard A, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, George G, Chinniah N, Halliday GM, Diona L, Damian DL. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer. Chemoprevention. N Engl J Med. 2015;373:1618–26CrossRefPubMed
Metadaten
Titel
Haut retten, Karzinome verhindern
Die Prävention und Therapie Aktinischer Keratosen
verfasst von
Prof. Dr. med. Harald P. M. Gollnick (em)
Publikationsdatum
02.05.2017
Verlag
Springer Medizin
Erschienen in
MMW - Fortschritte der Medizin / Ausgabe 8/2017
Print ISSN: 1438-3276
Elektronische ISSN: 1613-3560
DOI
https://doi.org/10.1007/s15006-017-9045-3

Weitere Artikel der Ausgabe 8/2017

MMW - Fortschritte der Medizin 8/2017 Zur Ausgabe

FORTBILDUNG . KRITISCH GELESEN

Raten Sie Schwangeren von Cannabis ab!

AUS DER PRAXIS VON HAUSARZT ZU HAUSARZT

Bei Personalsuche nicht in Diskriminierungsfalle tappen

AUS DER PRAXIS . DER HAUSARZT-REPORTER

Doc Klaus ist für die Ärmsten da

AKTUELLE MEDIZIN . MAGAZIN

Patient mit Synkope: Darf er ans Steuer?

AKTUELLE MEDIZIN

Was erzählt uns Paganinis Bogenhand?

FORTBILDUNG . SCHWERPUNKT

Typ-1-Diabetes, LADA oder „Doppeldiabetes“?

Weitere Lesetipps

ANZEIGE

Spektrum Dermatologie: Jetzt auch auf medbee – die App für Mediziner*innen

ANZEIGE

Dexpanthenol verstärkt die positiven Effekte der LASH-Methode

Natürlich schön: phytotherapeutische Ansätze in der ästhetischen Medizin

Versorgung von Menschen mit spastischer Bewegungsstörung nach Schlaganfall

Sehverschlechterung und gerötetes Auge – was war die Ursache?

ANZEIGE

Neue Konzepte beim Handekzem

Bildnachweise